Hemex Health

Executive Summary

Hemex Health is a Portland-based diagnostics company developing the Gazelle platform, a point-of-care diagnostic system that detects and quantifies blood-based conditions including sickle cell disease, beta thalassemia, and iron-related disorders. Founded in 2013, the company targets underserved populations in low-resource settings with a rapid, affordable, and portable testing solution. The Gazelle platform differentiates itself through its ability to deliver lab-quality results without complex infrastructure, addressing a critical gap in global health diagnostics. While still privately held with limited public financial data, Hemex Health’s focus on high-burden diseases and its innovative technology position it as a promising player in the decentralized diagnostics market. The company’s potential to disrupt traditional laboratory-based testing and expand access to essential diagnostics in emerging markets underpins its growth trajectory.

Upcoming Catalysts (preview)

• Q4 2026FDA Clearance or CE Mark for Gazelle Platform65% success
• Q3 2026Strategic Partnership with Global Health Organization70% success
• TBDSeries B or Later-Stage Funding Round60% success